Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Dornstadt – page 56

718 clinical trials in Dornstadt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dornstadt at a glance
718
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

718 trials in Dornstadt

Open in trial search

Partial seizures

Not recruiting

Study on ENX-101 for Treating Focal Epilepsy in Patients Using 1 to 4 Antiseizure Medications

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:ENX-101
  • Sponsor:Engrail Therapeutics Inc.

Plasma cell myeloma

Not recruiting

Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Renal cell carcinoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab for Patients with Kidney Cancer After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Burkitt's lymphoma+1

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed or Refractory Burkitt Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Kite Pharma Inc.

Hairy cell leukaemia

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Hairy Cell Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mesna
  • Sponsor:Kite Pharma Inc.

Richter's syndrome

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Kite Pharma Inc.

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Waldenstrom Macroglobulinemia Using a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Kite Pharma Inc.

Back pain

Not recruiting

Study on the Effectiveness and Safety of AP707 and Naproxen for Patients with Chronic Back Pain

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aceclofenac
  • Sponsor:Apurano Pharmaceuticals GmbH

Pain+1

Not recruiting

Study on the Effectiveness and Safety of AP707 with Lamotrigine and Amitriptyline for Patients with Chronic Central Neuropathic Pain

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adezunap
  • Sponsor:Apurano Pharmaceuticals GmbH

Pain+1

Not recruiting

Study on the Effectiveness of AP707, Gabapentin, and Capsaicin for Patients with Chronic Pain from Traumatic or Post-Operative Peripheral Neuropathy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adezunap
  • Sponsor:Apurano Pharmaceuticals GmbH

Study on the Effects of Obexelimab for Patients with IgG4-Related Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obexelimab
  • Sponsor:Zenas Biopharma (USA) LLC

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Dornstadt

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on ulcerative colitis treatment approaches. The trials evaluate novel oral therapeutic solutions aimed at achieving symptomatic remission and improving endoscopic outcomes in patients with mild to moderate disease activity.

  • Inflammatory Bowel Disease Management
  • Controlled Release Drug Delivery
  • Long-term Disease Control

These studies represent significant advances in developing targeted treatments for gastrointestinal inflammatory conditions, with potential benefits for patient quality of life and disease management strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.